Brief: Anpac Bio Successfully Completes Major Preclinical Study, Files With NMPA For Registration Testing Of Its Multi-Cancer Cda Device
23/08/2021 13:30
Aug 23 (Reuters) - AnPac Bio-Medical Science Co Ltd
ANPC.O :
* ANPAC BIO SUCCESSFULLY COMPLETES MAJOR PRECLINICAL STUDY,
FILES
WITH NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) FOR
REGISTRATION TESTING OF ITS MULTI-CANCER CDA DEVICE
Source text for Eikon: ID:nGNX4YRWkR
Further company coverage: ANPC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022